LATEST NEWS

Sep 21, 2021
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of the first, physician use only, polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
Jul 26, 2021
Cytox strengthens management team to support commercialisation of genoSCORE test to predict risk of cognitive decline due to Alzheimer’s disease
Jul 16, 2021
Cytox appoints BERBĒS as market developer in Spain, to introduce a new test that predicts the risk of cognitive decline due to Alzheimer’s disease

NEWSLETTERS

New Alzheimer’s Risk Test to launch in the US & Canada - Newsletter 6 Sept 2021
Cytox welcomes Aduhelm - Newsletter 5 July 2021
Cytox launches genoSCORE-LAB - Newsletter 4 Feb 2021

Meet the Team